Arvinas Inc (ARVN)
33.16
+0.92
(+2.85%)
USD |
NASDAQ |
May 31, 16:00
33.14
-0.02
(-0.06%)
After-Hours: 20:00
Arvinas Free Cash Flow: -356.00M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -356.00M |
| December 31, 2023 | -350.70M |
| September 30, 2023 | -339.80M |
| June 30, 2023 | -322.70M |
| March 31, 2023 | -313.40M |
| December 31, 2022 | -280.30M |
| September 30, 2022 | -245.60M |
| June 30, 2022 | 503.40M |
| March 31, 2022 | 535.50M |
| December 31, 2021 | 554.70M |
| September 30, 2021 | 561.53M |
| Date | Value |
|---|---|
| June 30, 2021 | -142.46M |
| March 31, 2021 | -117.79M |
| December 31, 2020 | -96.10M |
| September 30, 2020 | -83.33M |
| June 30, 2020 | -58.87M |
| March 31, 2020 | -52.10M |
| December 31, 2019 | -46.90M |
| September 30, 2019 | -41.78M |
| June 30, 2019 | -54.37M |
| March 31, 2019 | -50.72M |
| December 31, 2018 | -18.95M |
Free Cash Flow Range, Past 5 Years
-356.00M
Minimum
Mar 2024
561.53M
Maximum
Sep 2021
-37.35M
Average
-89.71M
Median
Free Cash Flow Benchmarks
| Pfizer Inc | 5.106B |
| Bristol-Myers Squibb Co | 12.51B |
| Alnylam Pharmaceuticals Inc | 127.82M |
| Rhythm Pharmaceuticals Inc | -140.47M |
| IDEAYA Biosciences Inc | -134.84M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -97.50M |
| Cash from Investing (Quarterly) | -127.80M |
| Cash from Financing (Quarterly) | 1.60M |
| Free Cash Flow Per Share (Quarterly) | -1.361 |
| Free Cash Flow to Equity (Quarterly) | -97.50M |
| Free Cash Flow to Firm (Quarterly) | -97.60M |
| Free Cash Flow Yield | -17.86% |